In developed countries, endometrial carcinoma is the most common cancer that affects the female genital tract. Endometrial carcinoma is divided into two main histological types, type I or endometrioid and type II or non-endometrioid, each of which have characteristic, although not exclusive, molecular alterations and mutational profiles. Nevertheless, information about the implication and relevance of some of these genes in this disease is lacking. We sought here to identify new recurrently mutated genes in endometrioid cancers that play a role in tumourigenesis and that influence the clinical outcome. We focused on low-grade, non-ultramutated tumours as these tumours have a worse prognosis than the ultramutated POLE-positive endometrioid endometrial carcinomas (EECs). We performed exome-sequencing of 11 EECs with matched normal tissue and subsequently validated 15 candidate genes in 76 samples. For the first time, we show that mutations in chromatin remodellingrelated genes (KMT2D, KMT2C, SETD1B and BCOR) and in DNA-repair-related genes (BRCA1, BRCA2, RAD50 and CHD4) are frequent in this subtype of endometrial cancer. The alterations to these genes occurred with frequencies ranging from 35.5% for KMT2D to 10.5% for BRCA1 and BCOR, with some showing a tendency toward co-occurrence (RAD50-KMT2D and RAD50-SETD1B). All these genes harboured specific mutational hotspots. In addition, the mutational status of KMT2C, KMT2D and SETD1B helps to predict the degree of myometrial invasion, a critical prognostic feature. These results highlight the possible implication of these genes in this disease, creating opportunities for new therapeutic approaches.
In developed countries, endometrial carcinoma (EC) is the most common cancer of the female genital tract. 1 Traditionally, EC has been divided into two main histological types. 2 Type I or endometrioid carcinomas (EECs) are usually oestrogen-related, well-differentiated low-grade carcinomas that occur in perimenopausal women. These tumours are usually related to a good prognosis, although metastatic and recurrent EECs represent a clinical challenge. Type II or nonendometrioid carcinomas (NEECs) are mainly represented by tumours with serous histology. They are more aggressive neoplasias that arise in older women, independently of oestrogen stimulation. Each of these two EC types have characteristic, although not exclusive, molecular features. 3, 4 EECs show frequent mutations in PTEN, PIK3CA, KRAS and CTNNB1, as well as displaying microsatellite instability (MSI). [5] [6] [7] [8] By contrast, NEECs are characterized by mutations in TP53 and PIK3CA, 9, 10 and by genomic instability reflected as a loss of heterozygosity (LOH) at multiple loci.
11 With regards to prognosis, ECs are classified into risk groups. 12, 13 While all NEECs are considered as high-risk cancers, EECs are divided as low, intermediate and high risk, based on the tumour architecture and degree of myometrial invasion: Grade 3 EECs that invade >50% of the myometrium depth and are considered as high risk; grade 3 tumours that invade <50% or grade 1-2 tumours that invade more than one half of the myometrium are of intermediate risk; and finally grade 1-2 tumours that do not invade more than one half of the muscle layer are categorized as low-risk carcinomas. 12 In recent years, The Cancer Genome Atlas Research Network (TCGA) has produced a vast amount of information on cancer genomics. Regarding ECs, 14 exome sequencing has revealed the existence of four tumour groups with different molecular and clinical behaviour: ultramutated tumours characterized by a very high mutation rate due to mutations in the POLE gene that encodes the epsilon catalytic subunit of DNA polymerase; a second hypermutated group that displays MSI and a high mutation rate; another cluster containing low copy-number alterations; and a fourth subgroup formed by those tumours with high copy-number variations (CNVs) and TP53 mutations, a group mainly composed of serous NEECs but that also includes grade 3 EECs. While the prognosis of the first group is good, the second and the third groups show similar and intermediate progression-free survival rates, and the prognosis associated with the fourth group of tumours is significantly worse. Up to 76% of POLE mutations affect two specific hotspots in exons 9 and 13, Val411Leu and Pro286Arg. 14, 15 These exons encode the domains responsible for POLE's proofreading activity and they accumulate 90% of the mutations described in this gene. 15 The TCGA EC study shows that although the most commonly mutated genes are well known, such as PTEN, PIK3CA, and so on, there are many genes that are mutated with an intermediate or low frequency in this disease and which role is poorly understood. In fact, other studies have shown that EC is among the solid tumours in which a larger number of genes are significantly mutated. 16, 17 Thus, identifying new biological pathways altered in EC could be important to improve the clinical management of this disease. This is especially relevant for low-grade tumours, where distinguishing between low-and high-risk disease is crucial. In this study, we sought to identify new recurrently mutated genes in EEC with a potential role in tumourigenesis and clinical progression, focusing on non-ultramutated grade 1/2 tumours that have a worse prognosis than the ultramutated POLE-positive EECs. To this end, we performed exome sequencing of 11 low-grade EEC samples with no mutations in POLE, using their corresponding normal tissue as a control. We selected candidate genes found to be mutated in these 11 samples and we analysed them in a validation study by full-length gene sequencing in a series of 76 EEC samples. Among the genes selected, we observed recurrent mutations in KMT2D, KMT2C, SETD1B, BRCA1, BRCA2, RAD50, BCOR and CHD4 at frequencies above 10% in our validations series. Moreover, when we analysed the clinical implications of the mutation of these genes using a clinical decision tree, we demonstrated the potential role of alterations in KMT2C, KMT2D and SETD1B to predict myometrial invasion. As shown by immunohistochemistry, there was weaker H3K4 methylation (the main function of these three genes) in tumour tissue than in normal endometrial tissue. These results highlight the relevance of the DNA damage repair and histone methylation in EEC.
Methods

Sample selection
In this study, we analysed 11 frozen grade 1 EEC samples with no mutations in the POLE gene and their corresponding normal tissue by exome sequencing (Table 1, 
top). In addition,
What's new?
This study aimed to identify new recurrently mutated genes that play a role in tumorigenesis and influence clinical outcome in endometrioid cancers, focusing on low-grade, non-ultramutated endometrioid endometrial carcinoma (EEC). For the first time, KMTT2D, KMT2C, SETD1B, BCOR, CHD4, RAD50, BRCA1 and BRCA2 were identified as genes related to chromatin remodelling and DNA repair and frequently mutated in non-ultramutated EEC. The mutational status of KMT2C, KMT2D and SETD1B helped predict the degree of myometrial invasion, a critical prognostic feature of this disease. This work provides relevant information regarding the mutational landscape of EEC, creating opportunities for new therapeutic approaches.
76 formalin-fixed paraffin-embedded (FFPE) grade 1/2 EEC samples (Table 1 , bottom) were used for the subsequent validation study. These samples harboured no mutations in POLE exons 9 and 13, the most frequently altered regions of this gene that contain the mutational hotspots Pro286 and Val411, respectively (determined by Sanger sequencing, data not shown). The samples were collected at the Hospital Universitari Vall d'Hebron (Barcelona), Hospital Universitari Arnau de Vilanova (Lleida), Hospital de la Santa Creu i Sant Pau (Barcelona), Complejo Hospitalario Universitario Santiago de Compostela (Santiago de Compostela) and the MD Anderson Cancer Center (Madrid).
DNA extraction and quantification
DNA was extracted by Proteinase K digestion, followed by phenol extraction and ethanol precipitation. The DNA was quantified by NanoDrop 2000 Spectrophotometer and Qubit 3.0 Fluorometer using a Qubit dsDNA BR Assay Kit (Life Technologies).
Exome sequencing, full-length gene sequencing and bioinformatics analysis
The exome sequencing, full-length gene sequencing and bioinformatics analysis are detailed in Supporting Information. Briefly, exome sequencing was performed using a SOLiD high-throughput platform and the DNA libraries were constructed using the Agilent SureSelectXT Human All Exon V4 1 UTR kit (71 Mb). To validate the results of the exome sequencing analysis, a selection of 15 candidate genes was sequenced in a series of 76 tumour samples. A gene panel was designed using the SureDesign platform (Agilent), and fragment libraries were obtained and captured using SureSelectXT Capture Library. Libraries were paired-end sequenced in an Illumina HiSeq 2000 machine. All the genomic positions are referred to the GRCh37/h19 assembly.
Statistical analyses, co-occurrence study and decision tree The mutation frequencies of the genes studied in our series were compared with those detected in the 131 data core grade 1/2 non-ultramutated EEC TCGA samples 14, 18, 19 using a Pearson's v 2 test and the SPSS software (significant p values are indicated: * 0.01 < p 0.05, ** 0.001 < p 0.01, and *** p 0.001). The tendency towards co-occurrence or mutual exclusivity between the mutated genes was determined as described previously 19 (see Supporting Information). The decision tree was generated using J48 algorithms with RWeka package of R software, considering only the samples with mutations in at least one of the genes analysed.
Sanger sequencing
A total of 13 variants detected by full-length gene sequencing (around 10% of the total) were validated by Sanger sequencing. Variants affecting mutational hotspots in KMT2D, KMT2C, SETD1B, BRCA1 and BCOR were validated by Sanger sequencing in 26 samples. POLE exons 9 and 13 were 
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sequenced in the 76 samples used in the full-length gene sequencing study. Primer sequences and amplicon lengths are indicated in Supporting Information, Table 1 .
Immunohistochemistry
Immunohistochemistries were performed on 2 mm FFPE tissue sections. Deparaffinization and antigen retrieval were done in a PT Link module (Dako), and immunohistochemistry was carried out in an Autostainer (Dako). The primary antibodies used were anti-H3 mono-methyl K4 (1:2500, Abcam ab8895), anti-H3 di-methyl K4 (1:1500, Cell Signaling Technologies 9725) and anti-H3 tri-methyl K4 (1:200, Cell Signaling Technologies 9725). The slides were counterstained with haematoxylin and evaluated by two independent pathologists. For the determination of microsatellite status, immunohistochemistry of MLH1, MSH2, MSH6 and PMS2 was performed according to Stelloo et al. 20 The antibodies used were from Dako. A sample was considered as MSI if one of these four markers showed negative expression. 20 
Ethics, consent and permissions
The study was approved by the Clinical Research Ethics Committee of the Hospital Universitario Ram on y Cajal (Madrid), and complete written informed consent was collected from all patients, through which the publication of the results obtained was accepted.
Availability of supporting data
The data discussed in this publication are deposited in NCBI's BioProject database and accessible through BioProject ID PRJNA313295 (http://www.ncbi.nlm.nih.gov/bioproject/ 313295).
Results
Identification of the mutational profile by exome sequencing of well-differentiated POLE-negative EECs
We sought to identify new genes altered in EECs to reveal novel biological pathways that potentially influence the pathogenesis of this disease, focusing on low-grade non-ultramutated tumours due to their relatively worse prognosis among low-grade tumours. We started by exome sequencing 11 lowgrade EEC specimens with no mutations in the POLE gene, using matched normal tissue as a control (Table 1 , top). The average depth of coverage for the exome sequencing of normal (36) and tumour samples (39) was similar, and we selected those single nucleotide variants (SNVs) and indels (insertions or deletions) with frequency above 0.15 and >10 reads (both in the tumour and normal tissue), to reduce the false-positive rate. Using these criteria, we detected 11,019 variants in the 11 tumour samples (including previously described SNPs, germline variants and somatic variants, regardless of their effect), with an average of 1,002 variants per sample, a median of 872 and a standard deviation (SD) of 715. Of the variants detected, 636 were indels and 10,383 were single base substitutions, 5,816 of which produced transitions and 4,567 transversions. After discarding population SNPs, germline and synonymous variants, we found some characteristic EEC mutations similar to those described previously (Supporting Information, Fig. 1 ): PTEN and ARID1A were mutated in 36.4% (4/11) of the samples; PIK3CA and PIK3R1 in 27.2% (3/11); CTNNB1, FGFR2 and FBXW7 in 18.2% (2/11); and KRAS in 9% (1/11). Moreover, we detected frequent mutations in other genes with a less established relevance in EC, such as KMT2C and PCDH9, each mutated in 27.2% (3/11) of the samples; or KMT2D, BRCA2 and RAD50 that were mutated in 18.2% (2/11).
DNA repair and chromatin remodelling-related genes are frequently mutated in low-grade EEC To gain more insight into the results obtained in the exome sequencing analysis, we validated a selection of candidate genes in a larger series of 76 grade 1/2 EEC samples with molecular, clinical and pathological features similar to those of the original cohort (Table 1, bottom). We focused on those genes that presented a higher mutational frequency in the exome analysis and studied them by full-length gene sequencing, selecting those genes that carried mutations in at least 2 samples and whose function or relevance in EEC tumourigenesis is poorly understood. Furthermore, we also included other genes in the validation study like SETD1B and BRCA1 that although only mutated in one sample, they are biologically related to KMT2C-KMT2D and BRCA2, respectively. 21, 22 In addition, PTEN was studied as a positive control. Thus, in our validation series (n 5 76), we sequenced 15 genes: KMT2D, CHD4, SETD1B, KMT2C, BCOR, BRCA2, RAD50, BRCA1, PCDH9, MTOR, NRIP1, SIN3A, SMARCA1, TDP1 and PTEN. According to the criteria defined in the Materials and Methods section, we detected 156 variants in these genes (excluding PTEN), as shown in Supporting Information, Table 2 . Indeed, 8 of these genes were seen to carry mutations in at least 10% of the samples (KMT2D, KMT2C, SETD1B, CHD4, BCOR, RAD50, BRCA1 and BRCA2), harbouring a total of 133 variants with a mean/median coverage of 379/375 (SD 5 196) and frequency of 0.43/0.46 (SD 5 0.1). All the variants in each gene and sample, with their predicted consequences and structural effects are shown in Supporting Information, Table 3 . In relation to these 8 genes, all of them had higher mutation frequencies (Fig. 1A) than those described in the TCGA core data set of grade 1/2 non-ultramutated samples (http:// www.cbioportal.org/ 18, 19 ), consisting of 186 samples. These differences were not significant for BCOR, BRCA2 and CHD4 (although CHD4 showed a tendency with a p value of 0.054). By contrast, the mutation frequencies of KMT2D, KMT2C, SETD1B, BRCA1 and RAD50 was significantly higher (Fig.  1A) , suggesting that these genes might be altered and in fact, more often than has previously been reported in this POLE non-mutated specific subtype of the disease. The PTEN mutation frequency detected by TCGA, and used here as a control of well-established EEC mutated gene, 7, 8, 14 was significantly higher than that detected in our series (Fig. 1A) .
The mutation frequency for these 8 genes ranged from 35.5% for KMT2D to 10.5% for BRCA1. Of the 133 variants detected, 104 (78.2%) were missense mutations, the most strongly represented category for each gene (Fig. 1B) . We detected 13 splice region variants (9.7%) in KMT2D, BCOR, CHD4, KMT2C and RAD50, as well as 9 frameshift mutations (6.8% of the total) affecting KMT2D, KMT2C and SETD1B. In addition, KMT2D and CHD4 also carried 3 inframe indels (2.3%), and BRCA2 harboured 4 nonsense mutations (3%). At least one of the three structural predictors indicated a potentially negative effect of the mutation in 59 of the 104 missense variants (56.7%), while for 30 variants (28.8%), the effect was unknown and 15 (14.4%) were predicted to be neutral (Fig. 1C) . To technically validate these results, we randomly selected 13 of these 133 variants (around 10%) and analysed them by Sanger sequencing. In all cases, the original data were validated (Supporting Information, Fig. 2) .
As non-ultramutated EECs can be divided into two different groups according to the presence or not of MSI (among other features), we studied any possible relation between mutations in these genes and microsatellite status, determined by immunohistochemistry of MLH1, MSH2, MSH6 and PMS2 20 ( Fig. 1D) . Even though the mutation frequencies of KMT2D, CHD4, SETD1B, RAD50 and KMT2C were higher among MSI tumours, the difference was significant only for KMT2C.
To detect any correlation in the alteration of distinct pathways in the same subset of samples, we studied the cooccurrence or mutual exclusivity of the changes to the 8 genes with a mutation frequency higher than 10% in our series. A significant tendency towards co-occurrence was observed only between KMT2D and RAD50 (p 5 0.04) and SETD1B and RAD50 (p 5 0.05, Fig. 2 ). RAD50 takes part in DNA damage repair, 23 while KMT2D and SETD1B are involved in chromatin remodelling through histone methylation. 21 This might suggest that alterations to DNA repair and histone methylation could coexist and contribute to EEC rising.
Identification of mutational hotspots in genes involved in chromatin remodelling and DNA repair
An important question is whether the variants detected mainly affect any specific domain of the proteins encoded by 
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Garc ıa-Sanz et al. these 8 genes. In general, some mutations were overrepresented in each of the genes, suggesting the existence of certain sites that are altered preferentially. The most obvious mutational hotspots were those detected in BCOR, BRCA1, KMT2D, SETD1B and KMT2C (Fig. 3) . In the case of BCOR and BRCA1, we found recurrent missense mutations in known protein domains (Figs. 3A and 3B ), as seen in the plot generated with MutationMapper 18, 19 that maps mutations in function of the Pfam protein domains. BCOR carries the missense variant Asn1459Ser in 6 samples, which maps one residue before the start of the Ankyrin-repeats domain and was also deleterious according to the three prediction tools. Moreover, of the 14 grade 1/2 non-ultramutated samples analysed by TCGA with mutations in BCOR, 7 (50%) carried this mutation, further evidence that it is a mutational hotspot in EEC. In the case of BRCA1, its serine-rich domain associated with BRCT carried the Gln356Arg substitution in 4 samples, a mutation predicted to be deleterious and possibly implicated in enhanced breast cancer susceptibility. These data suggest that these two domains may be important in the context of EEC tumourigenesis.
Although over-represented mutations were detected in KMT2D, SETD1B and KMT2C (Figs. 3C-3E ), these did not map to known protein domains. For KMT2D, two missense mutations were each detected in 8 samples (Arg83Gln and Ser4010Pro). Three samples carried a missense mutation in SETD1B (Leu1312Pro) and a frameshift mutation provoking truncation in other 3 samples (His8ProfsTer27, mapping to the N-terminus region of the protein). KMT2C also carried a truncating mutation in its middle region (Lys2797Argf-sTer26) that was detected in 4 samples. These two truncations provoke the loss of the catalytic SET domain in both proteins, which is responsible for lysine-methyltransferase activity. 24 Variants in the described mutational hotspots for BCOR, BRCA1, KMT2D, SETD1B and KMT2C were validated by Sanger sequencing in 26 samples (78.8% of the samples harbouring these variants), with a validation success rate of 100% ( Supporting Information, Fig. 3 ). Finally, RAD50 and CHD4 carried recurrent splice site mutations and substitutions, while BRCA2 harboured a stop-gain mutation in its C-terminal region (Lys3326Ter) that affected 3 samples (Supporting Information, Fig. 4 ).
Sequential analysis of the KMT2C-KMT2D-SETD1B mutational status predicts myometrial invasion in POLEnegative low-grade EECs
We set out to determine whether the mutational status of any of the genes identified might influence any aspect of the tumour phenotype. To this end, we analysed the correlation between the mutational status and clinically relevant tumour features, such as tumour grade and depth of myometrial invasion. We did not find a significant correlation between any of the individual mutated genes and these clinical parameters. Nevertheless, when considering the subset of genes related to H3K4 methylation (KMT2D, KMT2C and SETD1B) and their mutational status (wild type, mutations in one or mutations in more than one of them), a significant difference with respect to myometrial invasion was observed (p 5 0.005). Interestingly, tumours with mutations in only one of these genes showed a tendency towards weaker myometrial invasion (Fig. 4A) , a tumour feature related to better prognosis, 13 whereas when more than one of these genes was mutated a larger proportion of invasive tumours was observed. Moreover, the generation of a decision tree (considering only those samples that harboured at least one mutation in one of the 8 analysed genes and excluding those with no mutations) showed that together with tumour grade, the sequential analysis of the mutational status of KMT2C, KMT2D and SETD1B helped to predict if the depth of myometrial invasion is more or <50% (Fig. 4B) .
The global precision of the decision tree generated in predicting myometrial invasion was 85%. This decision tree indicated that if KMT2C was mutated and KMT2D was wild type, tumours were predicted to be non-invasive with a precision of 100%. If both KMT2C and KMT2D were mutated, tumours may show deep or superficial invasion, although in this case there were fewer cases such that the results must be taken with caution. Surprisingly, in this case, the tumours that underwent deep invasion were grade 1 carcinomas, while grade 2 tumours superficially invaded the myometrium. Conversely, when KMT2D was mutated in the absence of KMT2C mutations, it was necessary to analyse the status of SETD1B. When the latter was wild type, the tumour was very likely to be non-invasive, with a precision of 89%. If SETD1B was mutated, the tumour was more likely to invade the myometrium, although the precision was lower (60%). If KMT2C and KMT2D were wild type, it was again necessary to include SETD1B status in the decision tree. In this case, mutations in SETD1B predicted superficial myometrial invasion with a precision of 83%. Finally, if the three genes were wild type, grade 1 tumours tended to invade the myometrium, while grade 2 tumours did not.
Additionally, when we studied the correlation with the mutational status of these genes and clinical features in the 
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Garc ıa-Sanz et al. Figure 4 . The mutational profile of KMT2D, KMT2C and SETD1B is related to myometrial invasion. (A) Classification of the samples in our series as showing weak myometrial invasion (dark grey bars; tumour invades <50% of the myometrium thickness) or strong myometrial invasion (light grey bars; tumour invades >50% of the myometrium thickness), in function of the mutational status of KMT2D, KMT2D and SETD1B: No mutations, no mutations were detected in any of these genes; one gene mutated, only one of these genes carried a mutation; more than one gene mutated, mutations were detected in two or all three of these genes. The significance of the differences observed between the different groups was determined by the v 2 test: * 0.01< p 0.05, ** 0.001 < p 0.01 and *** p 0.001. (B) The generation of a decision tree shows the implication of KMT2D, KMT2C and SETD1B, and of the histological grade, in the prediction of myometrial invasion. In the diagram, the different mutational scenarios analysed in the decision tree are shown. A wild-type gene is indicated in green and a mutated gene in red in the boxes on the left, and the predicted invasive behaviour is shown in the boxes on the right (together with the corresponding precision of each prediction).
non-ultramutated EEC cases of the TCGA study ( Supporting  Information, Fig. 5 ), we observed a statistically significant higher proportion of KMT2C mutations in grade 3 cases compared to grade 1/2 cases, as well as more SETD1B mutations among those cases with deep myometrial invasion.
Immunohistochemical analysis of mono-, di-and trimethyl H3K4 shows lower methylation levels in EEC with respect to normal endometrium Finally, we addressed whether the mutational status of KMT2D, KMT2C and/or SETD1B affects the ability of these proteins to methylate H3K4 25 by analysing the levels of mono-, di-and tri-methyl H3K4 in our EEC samples through immunohistochemistry (Fig. 5 ). There was a tendency for tumour tissue to display less H3K4 methylation (mono-, diand trimethyl) than normal endometrial tissue (Fig. 5A) . Mono-and di-methyl H3K4 levels were homogenous and constant in the different samples studied. However, we observed two patterns of tri-methyl H3K4 immunostaining, with one group of samples showing homogeneous and relatively high tri-methylation levels, while a second smaller group showed more heterogeneous and lower levels, with areas of weak immunostaining (Fig. 5B) . We did not observe any clear relationship between this biphasic pattern and the genotype, such that further studies will be necessary to clarify this issue. Nevertheless, there was a significant relationship between architectural tumour grade and methylation, with a higher proportion of low tri-methyl H3K4 levels among the grade 2 tumours (Fig. 5C ).
Discussion
For the identification of new candidate genes involved in EEC tumorigenesis, the exome of a small series of low-grade POLE wild-type EEC samples was studied. Eight genes were found mutated in around 10% in this series as well as in a larger series of grade 1/2 EEC. The mutation frequencies of these genes were higher in our series than those detected in TCGA data core grade 1/2 non-ultramutated samples (except for BCOR), although it is important to consider the size difference between the two samples. These eight genes can be divided into two different functional groups: BRCA1, BRCA2, RAD50 and CHD4 are mainly involved in DNA damage repair; while KMT2C, KMT2D, SETD1B and BCOR are chromatin remodellers. Our data point to an implication of these mutations in carcinogenesis rather than in tumour progression, as they appear frequently in early stages of the disease. Nevertheless, the higher proportion of KMT2C and SETD1B mutations in grade 3 and deep myometrial invasion cases respectively in the TCGA study raises a question about this point.
With respect to the mutated genes, BCOR is a transcriptional co-repressor involved in the repression exerted by BCL6, 26 a master transcription factor that frequently suffers translocation in some types of lymphoma. 27 Somatic mutation of BCOR has been identified in acute myeloid leukemia 28 and six of the samples analysed here harboured a deleterious missense mutation (Asn1459Ser), the most frequent mutation among TCGA grade 1/2 non-ultramutated samples. This codon would therefore constitute a mutational hotspot in BCOR with potential involvement in EEC tumourigenesis. Asn1459 is located adjacent to the BCOR Ankyrin repeat, a region that is involved in protein-protein interactions according to UniProt database (http://www.uniprot.org/uniprot/Q6W2J9).
KMT2C, KMT2D and SETD1B take part in H3K4 methylation, one of the epigenetic mechanisms that regulate gene transcription. Specifically, the methylation of the histone H3 tail at Lysine 4 (H3K4) is related to the activation of transcription. 25 In humans, the addition of methyl groups to H3K4 is catalysed by the KMT2 family of methyltransferases, made up of KMT2A, KMT2B, KMT2C, KMT2D, SETD1A and SETD1B. 21 To date, many mutations in these genes have been identified in different human cancers, including ECs. 17 The high mutation frequency of these 3 genes in our series points to an important role for methylation in maintaining endometrial homeostasis, whereby its malfunction due to somatic mutations can provoke tumourigenesis. Moreover, we observed a tendency to dampen the mono-and dimethylation, and more significantly tri-methyl H3K4, in EEC tumour tissue with respect to normal endometrial tissue, even though this change was not clearly related to any specific mutational state.
Some members of the KMT2 family are altered in human disease, including cancer. 21, 24 One of the best characterized examples is that of a translocation in the KMT2A gene in leukaemia. 29 More recently, genomic studies including exome sequencing revealed alterations in KMT2C, KMT2D and SETD1B in different tumours. [30] [31] [32] [33] [34] Moreover, loss-of-function mutations in KMT2D are involved in Kabuki syndrome, a rare congenital disorder. 35 In our study, the distribution of the mutations in KMT2D, KMT2C and SETD1B, with two recurrent truncations in the two latter proteins, point to lossof-function as the likeliest global consequence of these variants, highlighting the probable relevance of H3K4 methylation in tumour development. Nevertheless, the specific pathogenic role or the clinical significance of such changes remains unclear.
We explored the possible correlation between mutations in these genes and phenotypic features of EEC closely related to disease prognosis, such as myometrial invasion or tumour grade. When the tumours studied were divided into three categories according to the mutational burden in these three genes (no mutations, only one gene mutated or more than one gene altered), there was a significant tendency towards superficial myometrial invasion in the tumours with mutations in just one of the genes than in the other two categories. Moreover, the generation of a decision tree suggests that the mutational status of KMT2C, KMT2D and SETD1B helps to predict the extent of invasion, although the biological mechanism of this relationship remains to be explored. According to our decision tree, carrying mutations in only one of these three genes, and especially in KMT2C or KMT2D, could be related to a weaker capacity of the tumour to invade the myometrium, a feature strongly related to good prognosis. This would imply that even though the malfunction of H3K4 methylation due to defects in these 3 genes is involved in EEC carcinogenesis, it may contribute to a less malignant phenotype in at least some circumstances. A drawback of the decision tree is that it was generated excluding those samples with no mutations in any of the 8 genes studied. Moreover, an important question that remains to be addressed is the possible correlation of the mutational status of these 8 genes with that of other EEC-related genes which may play a role in the disease and specifically in myometrial invasion. Although the involvement of specific mutations in myometrial invasion remains controversial, 4 some studies have shown a possible correlation between mutations in PIK3CA and deep invasion, 36 so knowing the status of such genes in our series would add value to this study. In the TCGA study, although the mutational frequency of these 8 genes is different to that observed in our series, some of them show significant tendency towards co-occurrence with known EEC genes, such as PTEN or PIK3R1 (not shown).
We did not find a tendency towards co-occurrence of the mutations affecting KMT2D, KMT2C and SETD1B, suggesting that mutation in just one of them is the main event by which this pathway is affected in low-grade EECs. The fact that the mutations most often found in KMT2C and SETD1B produce a truncation points to a tumour suppressor role for these genes. This is consistent with KMT2C and KMT2D suppressing tumourigenesis in mice, as targeted inactivation of KMT2C results in epithelial tumours of the ureter.
37
KMT2C and KMT2D contribute to the methylation of H3K4 in enhancer elements, genomic regions important for transcriptional activation. 38 There are two possible explanations as to how mutations in these proteins affect enhancer function and contribute to tumourigenesis 39 : Defective KMT2 proteins may prevent the enhancer from adopting its active conformation, thereby dampening the transcription of tumour-suppressor genes; or mutations in these proteins may increase their affinity for the enhancer region, augmenting its activity and contributing to the overexpression of oncogenes. According to our results, the first scenario seems more plausible in EEC. There has been some effort to clinically target histone methylation, including the development of small molecule inhibitors of methylation. 40 Some of these have anti-tumoural activity in KMT2A-translocated leukaemia cells, 41 and they may inhibit the interaction between KMT2A and menin, part of the histone methylation complex. 42 However, the potential utility of these in the context of EEC remains to be explored.
The rest of the genes analysed in this study are involved in DNA damage repair. The CHD4 protein is recruited to DNA damage sites, creating a favourable environment for the repair function. 43 CHD4 mutations have been previously described in EC, 44 although in the serous subtype, which tumourigenesis and clinical evolution are different of those of EEC. RAD50 takes part in the DNA damage response, in part by mediating the activation of ATM, 23 and germline mutations in RAD50 have been reported with low frequency in inherited non-BRCA1/2 breast cancers. 45 Importantly, in our study, there was a significant tendency for mutations in RAD50 to co-occur with those in SETD1B and KMT2D. Thus, the RAD50-mediated DNA repair could be important for EEC development in the context of H3K4 methylation defects.
BRCA1 and BRCA2 are essential components of the DNA repair machinery, 22 and their relevance in cancer development and susceptibility is well-established. More recently, somatic mutations in both genes have been shown to be frequent in ovarian cancer. 46 Tumours with impaired BRCA1/2 are particularly sensitive to DNA-damaging therapeutic agents 47 and our results suggest a certain potential for therapeutic strategies directed towards BRCA-deficiency in BRCA1/2 mutated endometrial tumours. Further studies would be required to test this hypothesis.
In conclusion, our results shed light on the complex mutational landscape of EECs, focusing on low-grade nonultramutated tumours, showing for the first time the relatively high frequency of mutation of histone methylation (KMT2C, KMT2D and SETD1B) and DNA damage repair (BRCA1, BRCA2, CHD4 and RAD50) related genes. These pathways could influence the development of the disease, either alone or in conjunction. Importantly, DNA repair emerges as a pivotal biological pathway involved in EEC carcinogenesis, through the alteration of POLE, mismatch repair and/or mutations in at least BRCA1, BRCA2, CHD4 or RAD50. According to our results, these mutations could be important for tumour initiation, while its involvement in tumour progression remains to be studied. Further research would be necessary to validate these observations in larger cohorts, as well as to study the possible correlation of these mutations with other known mutations. These results may contribute to explain this tumour's biology, providing opportunities for the discovery of surrogate markers which could be useful for the diagnosis of the disease, and also paving new ways for new therapeutic approaches based on the modulation of histone methylation and DNA repair, which would require further extensive research both in vitro and in vivo.
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